Prevents Viral Replication
A new drug for treatment of hepatitis C launched by State Company R-Pharm will soon be available in Russian pharmacies. Narlaprevir, NS3 protease inhibitor will become the first drug for chronic viral hepatitis C in the form of tablets.
Narlaprevir is highly effective, convenient for use and has improved safety profile. It affects NS3 serine viral protease and prevents its replication in infected host cells.
Results of a large-scale clinical study PIONEER held in 2016 at twenty leading Russian sites where treatment of viral hepatitis, have confirmed the efficacy and safety of narlaprevir. According to the experts it is comparable to foreign drugs and should be included into hepatitis C clinical treatment guidelines. R-Pharm is planning to initiate inclusion of narlaprevir into the list of Essential and life-saving medicinal drugs in the Russian Federation, thus expanding opportunities of recovery of Russian patients with chronic hepatitis C.
The drug will be manufactured at the Yaroslavl plant of finished pharmaceutical forms of R-Pharm, complying with Russian and international GMP standards.
Soon an oral narlaprevir-based combination for treatment of chronic hepatitis C will be developed, which will make it possible to cure the disease without pegylated interferons.